Convergent action on AMR identified as an important area of intervention
Patent Term Extension is designed to restore some of the patent life lost during the regulatory review process for new drugs.
Construction will begin this year with the new capacity anticipated by 2025
Acuitas Therapeutics' LNP technology will support Bayer’s in vivo gene editing and protein replacement programs with the goal of specifically delivering RNA payloads to the desired target organ, the liver.
The development and deployment of effective vaccines can help to mitigate the impact of pandemics, and we must prioritize research efforts to achieve this objective
The drug exhibited greater treatment persistence and control of moderate-to-severe PsO symptoms compared to secukinumab and ixekizumab
Two patents were filed during the quarter ended 31st March, 2023 and the cumulative filings till date are 3239
Subscribe To Our Newsletter & Stay Updated